NCT07340788Not yet recruiting
Amylin-Induced Migraine Attacks Without Aura
Amylin-Induced Migraine Attacks Without Aura: A Randomized Clinical Trial
Source: ClinicalTrials.gov · Last updated 14 Jan 2026
Brief summary (registry, in English)
Pramlintide is a peptide analogue of human amylin which is a vasoactive signaling molecule involved in the pathogenesis of migraine. This study investigates whether pramlintide induces migraine attacks without aura in people with migraine without aura.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- First submitted
- 5 Jan 2026
- Start date
- Feb 2026
- Primary completion date
- 30 Oct 2028
- Lead sponsor
- Danish Headache Center
- Diseases
- Migraine
- NCT number
- NCT07340788
What you commit to
- Study type: Interventional
- Planned participants: 21
- From Feb 2026 to the primary completion date, 30 Oct 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Hypertension (systolic blood pressure of ≥150 mmHg and/or diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day
- Daily use of any medication other than contraceptives
- Intake of any medication other than contraceptives within 48 hours of infusion start
Other illness
- Any history of a primary or secondary headache disorder other than migraine without aura and infrequent episodic tension-type headache
- Any history of moderate to severe traumatic brain injury
- Any history of cardiovascular disease, including cerebrovascular diseases
- Any history of pulmonary disease
- Any other clinically significant disorders, conditions, or diseases that might impact the safety of the subject or interfere with the study's evaluation, procedures, or completion, aside from those mentioned above. This includes any relevant medical history or evidence that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results
- Cardiovascular disease of any kind, including cerebrovascular diseases
Other
- The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior
- Female subjects of childbearing potential with a positive pregnancy test during any study visit
- Hypotension (systolic blood pressure of ≤90 mmHg and/or diastolic blood pressure of ≤50 mmHg)
- Abnormalities on the electrocardiogram that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results
- Intake of caffeine, nicotine, and alcohol within 12 hours of infusion start
- Headache of any intensity within 48 hours of infusion start
- Migraine attack within 48 hours of infusion start
- Aura within 48 hours of infusion start
Who the study is looking for
- Age 18 to 65 years of age upon entry into screening
- A body weight of 50 to 100 kg
- History of migraine without aura for ≥12 months and in accordance with ICHD-3
- Between 1-5 monthly migraine days without aura on average across the 3 months prior to screening
- Provision of informed consent prior to initiation of any study-specific activities/procedures
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rigshospitalet Glostrup Coordinator of this site? Confirm its status | Glostrup Municipality | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.